Cargando…
The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR–ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents
Chronic myeloid leukaemia is typically characterised by the presence of dysregulated BCR–ABL tyrosine kinase activity, which is central to the oncogenic feature of being resistant to a wide range of cytotoxic agents. We have investigated whether the inhibition of this tyrosine kinase by the novel co...
Autores principales: | Liu, W M, Stimson, L A, Joel, S P |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375377/ https://www.ncbi.nlm.nih.gov/pubmed/11986783 http://dx.doi.org/10.1038/sj.bjc.6600288 |
Ejemplares similares
-
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation
por: Deutsch, E, et al.
Publicado: (2004) -
β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation
por: Qin, R, et al.
Publicado: (2014) -
A combination of STI571 and BCR-ABL1 siRNA with overexpressed p15INK4B
induced enhanced proliferation inhibition and apoptosis in chronic myeloid
leukemia
por: Xia, D.Y., et al.
Publicado: (2014) -
Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018) -
Dual transcripts of BCR-ABL & different polymorphisms in chronic myeloid leukaemia patients
por: Nandagopalan, S. Rajashree, et al.
Publicado: (2016)